“`html
Niraparib CNS Penetration Assessment in Glioblastoma Patients
Practical Solutions and Value
- Niraparib is a drug approved for ovarian cancer maintenance therapy and under development for glioblastoma and other cancers.
- A new method to measure niraparib levels in human brain tumor tissue and cerebrospinal fluid (CSF) has been developed.
- The method was validated using plasma as a surrogate matrix, ensuring accuracy and precision.
- Niraparib was found to be stable in human brain homogenate, stock, and working solutions, allowing reliable measurements.
- The method is currently being used in an ongoing clinical trial on glioblastoma and recurrent IDH1/2(+) ATRX mutant glioma patients.
- Initial results show significant brain penetration ability of niraparib in glioblastoma patients, indicating its potential effectiveness in treating this type of cancer.
“`
